Astellas Pharma (ALPMY) Projected to Post Earnings on Wednesday

Astellas Pharma (OTCMKTS:ALPMY) is anticipated to issue its results after the market closes on Wednesday, November 4th. Analysts expect Astellas Pharma to announce earnings of $0.4113 per share and revenue of $3.79 billion for the quarter.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $16.16 on Monday. The company has a market cap of $29.24 billion, a P/E ratio of 12.30 and a beta of 0.08. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $14.98 and a 200 day moving average price of $14.71. Astellas Pharma has a 52 week low of $10.05 and a 52 week high of $17.35.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.

Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.